32 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
8 May 24
Zai Lab Announces First Quarter 2024
4:09pm
):
–In April 2024, Zai Lab submitted an sBLA for efgartigimod SC for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP … to initiate a global Phase 2 study in mild-to-moderate chronic plaque psoriasis in the second quarter of 2024.
Conference Call and Webcast Information
8-K
EX-99.1
h1net 7dqebrxk
27 Feb 24
Zai Lab Announces Full-Year 2023
4:12pm
8-K
EX-99.1
5vww2a22 m2g
7 Nov 23
Zai Lab Announces Third Quarter 2023
4:10pm
8-K
EX-99.1
xkn imoe9d
7 Aug 23
Zai Lab Announces Second Quarter 2023
4:07pm
8-K
EX-99.1
ek9 s7ja7
30 Jun 23
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
4:18pm
8-K
EX-99.1
k9ctdfgg
9 May 23
Zai Lab Announces First Quarter 2023
4:03pm
8-K
EX-99.1
ujrtxq
9 Nov 22
Zai Lab Announces Third Quarter 2022
4:13pm
8-K
EX-99.1
htvp o948aiez2uu
9 Aug 22
Zai Lab Announces Second Quarter 2022
12:00am
8-K
EX-99.1
m60h8k
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
8-K
EX-99.1
vh2ixzlasn
1 Mar 22
Results of Operations and Financial Condition
4:17pm